IP Library Patent Application 18209810
Patent Application
App. No. 18/209,810

METHODS FOR TREATING HORMONAL DISORDERS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/209,810
Abstract

A method of treating a subject, the method comprises applying an alternating electric field focused on a liver of the subject at a frequency between approximately 50 kHz and approximately 10,000 kHz, where the subject has hormonal disorder and/or polycystic ovary syndrome.

Claims (27)

1 . A method of treating a subject, comprising:

applying an alternating electric field focused on a liver of the subject at a frequency between approximately 50 kHz and approximately 10,000 kHz, wherein the subject has polycystic ovary syndrome.

2 . The method of claim 1 , wherein the frequency is between approximately 150 kHZ and approximately 200 kHZ.

3 . The method of claim 1 , wherein the alternating electric field is administered to the subject by cycling between a predetermined treatment time period when the alternating electric field is applied to the subject and a predetermined rest time period when the alternating electric field is not applied to the subject.

4 . The method of claim 3 , wherein the predetermined treatment time period is between approximately one hour to approximately 72 hours,

wherein the predetermined rest time period is approximately a week.

5 . The method of claim 1 , further comprising administering an additional therapy for treating the polycystic ovary syndrome, wherein the additional therapy comprises an administration of a metformin (MET), a glucagon-like peptide-1 receptor agonist (GLP-1 RA), a thiazolidinedione (TZD), a compound oral contraceptive (COCs), or a combination thereof.

6 . The method of claim 1 , further comprising diagnosing a subject with at least one of polycystic ovary syndrome, wherein the additional therapy comprises a surgery, and/or an administration of a medicine selected from the group consisting of a metformin (MET), a tamoxifen, a clomiphene citrate, a glucocorticoid, a gonadotropin, an aromatase inhibitor, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), a thiazolidinedione (TZD), a compound oral contraceptive (COCs), and a combination thereof.

7 . The method of claim 6 , wherein the subject is not diagnosed as having a cancer.

8 . A method of treating a subject, comprising:

increasing a level of Sex Hormone Binding Globulin (SHBG) in blood of the subject by applying the alternating electric field focused on the liver of the subject.

9 . The method of claim 8 , wherein the level of SHBG in the blood of the subject is less than approximately 144 nmol/L before applying the alternating electric field to the liver of the subject.

10 . The method of claim 8 , further comprising measuring the level of SHBG in the blood of the subject after applying the alternating electric field to the liver of the subject.

11 . The method of claim 8 , wherein the level of SHBG in the blood of the subject is between approximately 18 nmol/L to approximately 144 nmol/L after applying the alternating electric field to the liver of the subject.

12 . The method of claim 8 , wherein a level of SHBG-testosterone complex is increased in the blood of the subject after applying the alternating electric field.

13 . The method of claim 8 , wherein, when the alternating electric field is applied, the subject has a diagnosis of at least one of polycystic ovary syndrome, a reduced level of Sex Hormone Binding Globulin (SHBG), or an elevated level of circulating testosterone.

14 . The method of claim 13 , wherein, when the alternating electric field is applied, the subject does not have a diagnosis of cancer.

15 . A method of treating a subject, comprising:

applying an alternating electric field to the subject at a frequency between approximately 50 kHz and approximately 10,000 kHz to affect a level of circulating testosterone in the subject,

wherein blood of the subject has a first level of circulating testosterone before applying the alternating electric field,

wherein blood of the subject has a second level of circulating testosterone after applying the alternating electric field,

wherein the second level of circulating testosterone is less than the first level of circulating testosterone.

16 . The method of claim 15 , wherein the first level of the circulating testosterone is greater than or equal to approximately 70 ng/dL or greater than or equal to approximately 2.4 nmol/L.

17 . The method of claim 15 , wherein the second level of the circulating testosterone is less than or equal to approximately 70 ng/dL or less than or equal to approximately 2.4 nmol/L.

18 . The method of claim 15 , further comprising measuring the level of the circulating testosterone in the blood of the subject before and after applying the alternating electric field to the subject.

19 . The method of claim 15 , wherein the alternating electric field is focused on at least one of a liver cell, an ovarian cell, or a brain cell.

20 . The method of claim 15 , further comprising diagnosing a subject with polycystic ovary syndrome, a reduced level of Sex Hormone Binding Globulin (SHBG), and/or an elevated level of circulating testosterone.

Assignments (3)
PATENT SECURITY AGREEMENT Recorded May 4, 2024
From: NOVOCURE GMBH (SWITZERLAND)
To: BIOPHARMA CREDIT PLC
Reel/Frame 067315/0399 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THE RECEIVING PARTY DATA PREVIOUSLY RECORDED AT REEL: 064275 FRAME: 0128. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jul 24, 2023
From: AVIGDOR, LILACH; VOLOSHIN-SELA, TALI
To: NOVOCURE GMBH
Reel/Frame 064491/0941 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2023
From: AVIGDOR, LILACH; VOLOSHIN-SELA, TALI
To: VERISIGN, INC.
Reel/Frame 064275/0128 →